Literature DB >> 10029871

Anti-epileptic drug intake adherence. The value of the blood drug level measurement and the clinical approach.

M da M Gomes1, H de S Maia Filho, R A Noé.   

Abstract

It was evaluated the patient antiepileptic drug (AED) intake adherence in a pilot cross-sectional study carried out at a neurologic out-patient clinic of a university hospital. Ninety-three AED blood concentration (phenobarbital, phenytoin, carbamazepine) were analyzed from 24 patients. The variability of the AED blood level was measured (in the steady state period by means of the variation coefficient) and compared with the self-reported antiepileptic medication non-adherence, AED blood level according to the range (therapeutic or not), and the seizure control. It was not observed any strong correlation between the higher value of variability and the other three parameters of no adherence. The highest correlation was with the blood drug level (therapeutic or not). The evaluation of blood drug measurement alone, except in cases of extreme low adherence and variability of drug intake, is not enough for the recognition of incorrect drug intake, but the clinical markers and the self-reported adherence have to be also considered for this sort of evaluation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10029871     DOI: 10.1590/s0004-282x1998000500002

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN: 0004-282X            Impact factor:   1.420


  8 in total

1.  Pharmacokinetically and clinician-determined adherence to an antidepressant regimen and clinical outcome in the TORDIA trial.

Authors:  Hiwot Woldu; Giovanna Porta; Tina Goldstein; Dara Sakolsky; James Perel; Graham Emslie; Taryn Mayes; Greg Clarke; Neal D Ryan; Boris Birmaher; Karen Dineen Wagner; Joan Rosenbaum Asarnow; Martin B Keller; David Brent
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2011-03-09       Impact factor: 8.829

2.  Adherence to medication among outpatient adolescents with epilepsy.

Authors:  Wael M Gabr; Mohamed E E Shams
Journal:  Saudi Pharm J       Date:  2014-05-26       Impact factor: 4.330

Review 3.  A systematic review and meta-analysis of anti-epileptic medication non-adherence among people with epilepsy in Ethiopia.

Authors:  Zelalem Belayneh; Birhanie Mekuriaw
Journal:  Arch Public Health       Date:  2020-05-01

4.  Risk factors associated with the epilepsy treatment gap in Kilifi, Kenya: a cross-sectional study.

Authors:  Caroline K Mbuba; Anthony K Ngugi; Greg Fegan; Fredrick Ibinda; Simon N Muchohi; Christopher Nyundo; Rachael Odhiambo; Tansy Edwards; Peter Odermatt; Julie A Carter; Charles R Newton
Journal:  Lancet Neurol       Date:  2012-07-06       Impact factor: 44.182

5.  Evaluation of Kilifi epilepsy education programme: a randomized controlled trial.

Authors:  Fredrick Ibinda; Caroline K Mbuba; Symon M Kariuki; Eddie Chengo; Anthony K Ngugi; Rachael Odhiambo; Brett Lowe; Greg Fegan; Julie A Carter; Charles R Newton
Journal:  Epilepsia       Date:  2014-01-21       Impact factor: 5.864

6.  Epilepsy care cascade, treatment gap and its determinants in rural South Africa.

Authors:  Ryan G Wagner; Chodziwadziwa W Kabudula; Lars Forsgren; Fredrick Ibinda; Lars Lindholm; Kathleen Kahn; Stephen Tollman; Charles R Newton
Journal:  Seizure       Date:  2020-06-09       Impact factor: 3.184

7.  Identification and prevention of antiepileptic drug noncompliance: the collaborative use of state-supplied pharmaceutical data.

Authors:  Joseph C Hodges; Janet Treadwell; Amy D Malphrus; Xuan G Tran; Angelo P Giardino
Journal:  ISRN Pediatr       Date:  2014-02-19

8.  Magnitude and factors associated with nonadherence to antiepileptic drug treatment in Africa: A cross-sectional multisite study.

Authors:  Fredrick Ibinda; Peter Odermatt; Symon M Kariuki; Angelina Kakooza-Mwesige; Ryan G Wagner; Seth Owusu-Agyei; Honorati Masanja; Anthony K Ngugi; Caroline K Mbuba; Victor C K Doku; Brian G Neville; Josemir W Sander; Charles R J C Newton
Journal:  Epilepsia Open       Date:  2017-03-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.